Sorrento Therapeutics (SRNE) Competitors $0.0013 0.00 (-7.14%) As of 07/3/2025 12:54 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsInsider TradesSEC FilingsShort InterestSustainabilityTrendsBuy This Stock SRNE vs. SPRB, ENVB, GLMD, ELAB, AFMD, PRFX, ADTX, PBM, OGEN, and GRIShould you be buying Sorrento Therapeutics stock or one of its competitors? The main competitors of Sorrento Therapeutics include Spruce Biosciences (SPRB), Enveric Biosciences (ENVB), Galmed Pharmaceuticals (GLMD), PMGC (ELAB), Affimed (AFMD), PainReform (PRFX), Aditxt (ADTX), Psyence Biomedical (PBM), Oragenics (OGEN), and GRI Bio (GRI). These companies are all part of the "pharmaceutical products" industry. Sorrento Therapeutics vs. Its Competitors Spruce Biosciences Enveric Biosciences Galmed Pharmaceuticals PMGC Affimed PainReform Aditxt Psyence Biomedical Oragenics GRI Bio Sorrento Therapeutics (NASDAQ:SRNE) and Spruce Biosciences (NASDAQ:SPRB) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, valuation, institutional ownership, media sentiment, dividends, earnings and risk. Which has more volatility and risk, SRNE or SPRB? Sorrento Therapeutics has a beta of 0.98, meaning that its share price is 2% less volatile than the S&P 500. Comparatively, Spruce Biosciences has a beta of 2.4, meaning that its share price is 140% more volatile than the S&P 500. Do analysts recommend SRNE or SPRB? Spruce Biosciences has a consensus price target of $1.75, indicating a potential upside of 2,317.13%. Given Spruce Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Spruce Biosciences is more favorable than Sorrento Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sorrento Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Spruce Biosciences 0 Sell rating(s) 6 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Is SRNE or SPRB more profitable? Sorrento Therapeutics has a net margin of 0.00% compared to Spruce Biosciences' net margin of -555.23%. Sorrento Therapeutics' return on equity of 0.00% beat Spruce Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Sorrento TherapeuticsN/A N/A N/A Spruce Biosciences -555.23%-62.10%-47.49% Do institutionals and insiders believe in SRNE or SPRB? 0.0% of Sorrento Therapeutics shares are held by institutional investors. Comparatively, 91.7% of Spruce Biosciences shares are held by institutional investors. 2.6% of Sorrento Therapeutics shares are held by insiders. Comparatively, 6.9% of Spruce Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the media prefer SRNE or SPRB? In the previous week, Spruce Biosciences had 1 more articles in the media than Sorrento Therapeutics. MarketBeat recorded 2 mentions for Spruce Biosciences and 1 mentions for Sorrento Therapeutics. Sorrento Therapeutics' average media sentiment score of 0.00 equaled Spruce Biosciences'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sorrento Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Spruce Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has stronger valuation & earnings, SRNE or SPRB? Spruce Biosciences has lower revenue, but higher earnings than Sorrento Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSorrento Therapeutics$60.32M0.01-$572.84MN/AN/ASpruce Biosciences$4.91M0.62-$47.92M-$1.32-0.05 SummarySpruce Biosciences beats Sorrento Therapeutics on 8 of the 12 factors compared between the two stocks. Get Sorrento Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SRNE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SRNE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SRNE vs. The Competition Export to ExcelMetricSorrento TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$717K$205.22M$5.56B$9.03BDividend YieldN/AN/A5.22%3.99%P/E RatioN/AN/A27.6920.25Price / Sales0.01223.65386.46160.70Price / CashN/A22.4436.8958.10Price / BookN/A5.618.035.67Net Income-$572.84M-$96.61M$3.18B$249.21M7 Day PerformanceN/A-0.57%2.93%3.28%1 Month PerformanceN/A-3.74%1.72%3.95%1 Year PerformanceN/A10.50%34.39%20.98% Sorrento Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SRNESorrento Therapeutics0.6945 of 5 stars$0.00-7.1%N/A-88.2%$717K$60.32M0.00800News CoverageGap DownHigh Trading VolumeSPRBSpruce Biosciences2.174 of 5 stars$0.07+0.7%$1.75+2,313.8%-87.3%$3.06M$4.91M-0.0820News CoverageGap DownENVBEnveric Biosciences2.6041 of 5 stars$1.21-2.4%$10.00+726.4%-83.6%$3.06MN/A-0.0320GLMDGalmed PharmaceuticalsN/A$1.84+1.7%N/A-52.1%$2.99MN/A-0.1120Positive NewsELABPMGC0.0722 of 5 stars$2.16+0.9%N/A-99.7%$2.94M$1.71M0.0018Gap UpAFMDAffimed2.9627 of 5 stars$0.18-34.9%$3.62+1,895.9%-96.4%$2.92M$877K0.00200Gap DownHigh Trading VolumePRFXPainReform0.7329 of 5 stars$1.44+2.1%N/A-22.1%$2.84MN/A-0.014Positive NewsADTXAditxtN/A$1.28-3.8%N/A-100.0%$2.82M$130K0.0060News CoveragePBMPsyence BiomedicalN/A$5.33+8.6%N/A-96.9%$2.80MN/A0.00N/AGap UpOGENOragenics0.2144 of 5 stars$3.82-5.7%N/A-95.1%$2.73M$40K-0.545Gap DownGRIGRI Bio3.2929 of 5 stars$1.29+1.6%$22.00+1,605.4%-94.6%$2.72MN/A-0.111 Related Companies and Tools Related Companies Spruce Biosciences Competitors Enveric Biosciences Competitors Galmed Pharmaceuticals Competitors PMGC Competitors Affimed Competitors PainReform Competitors Aditxt Competitors Psyence Biomedical Competitors Oragenics Competitors GRI Bio Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SRNE) was last updated on 7/6/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredWhy Elon is funding the “Quantum Power Grid”Elon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s BIGGEST setup yet.After another undefeated quarter, “Market Wizard” Larry Benedict is sounding the alarm on a $194 trillion mark...Brownstone Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sorrento Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sorrento Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
